# US 2024/0391948 A1 · Novel compound that inhibits tnf-alpha generation and inflammasome activity and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391948 A1
- Document ID: US20240391948A1
- Status: Published application
- Kind: A1
- Application number: 18/292,654
- Filed: 2022-07-26
- Published: 2024-11-28
- Earliest claimed: 2021-07-26
- Assignees: Shaperon Inc.; Seoul National University R&Db Foundation
- Applicants: Shaperon Inc.; Seoul National University R&Db Foundation
- Inventors: Seung Yong SEONG
- Web page: https://patentgrep.com/patent/US20240391948A1

## CPC

- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07J 41/0066: {the 17-beta position being substituted by a carbon atom forming part of an amide group}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- C07J 41/0061: {one of the carbon atoms being part of an amide group}
- C07J 43/003: {not condensed}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a novel compound and a preparation method therefor. The compound according to the present invention exhibits inhibitory activity against the generation of TNF-α that is an inflammatory cytokine produced by inflammation initiation reaction, and against the generation of IL-1β by inflammasome activation, and thus, can be developed as a therapeutic agent for related inflammatory diseases.

## Claims

### Claim 1

A compound represented by formula 1 or a pharmaceutically acceptable salt thereof:
wherein,
R1, R2, R3 and R4 are each independently H, halo, C1-5 alkyl, OH, or =O,
X is substituted or unsubstituted C1-10 alkylene,
wherein when X is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-10 alkyl, halo, OH, SH, NH2, CONH2, or COOH,
A is C1-10 alkylene, C1-10 heteroalkylene, C1-10 alkenylene, C1-5 alkynylene, C3-8 cycloalkylene, C3-8 heterocycloalkylene, C6-20 arylene, C6-20 heteroarylene, —NR5R6C(O)—, —OR6, —SR6, —NR5R6, —C(O)R6, —C(O)OR6, —C(O)NR5R6, —CH(R5)(R6), —CH(R5)(OR6), —CH(OR5)(OR6), —CH(R5)(SR6), or —CH(SR5)(SR6);
R5 is H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C1-10 heteroalkyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted C3-20 heterocycloalkyl, substituted or unsubstituted C6-20 aryl, substituted or unsubstituted C6-20 heteroaryl, substituted or unsubstituted C1-10 alkyl-C6-20 cycloalkyl, substituted or unsubstituted C1-10 alkyl-C6-20 heterocycloalkyl, substituted or unsubstituted C1-10 alkyl-C6-20 aryl or substituted or unsubstituted C1-10 alkyl-C6-20 heteroaryl,
wherein if R5 is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, =O, ORa, SRa, N(Ra)2, or CON(Ra)2, and Ra is H or C1-5 alkyl,
R6 is a bond, substituted or unsubstituted C1-10 alkylene, substituted or unsubstituted C1-10 heteroalkylene, substituted or unsubstituted C3-20 cycloalkylene, substituted or unsubstituted C3-20 heterocycloalkylene, substituted or unsubstituted C6-20 arylene, or substituted or unsubstituted C6-20 heteroarylene,
wherein if R6 is substituted, one or more hydrogen(s) is(are) substituted with ═O, linear or branched C1-10 alkyl, C0-10 alkyl-C6-20 aryl, C0-10 alkyl-OH, C0-10 alkyl-NH2, C0-10 alkyl-SH, or C0-10 alkyl-CONH2; or R5 and R6 together form C3-20 cycloalkylene, C3-20 heterocycloalkylene, C6-20 arylene or C6-20 heteroarylene;
Y combines directly with A or with R6, and is H, —(CH2)nCH3, —(CH2)nCOOH, —(CH2)nOH—(CH2)nSO3H, —(CH2)nOSO3H, —(CH2)nPO3H2, —(CH2)nOPO3H2, —(CH2)nSO3NH2, —(CH2)nCONH2, or —(CH2)nC(O)SO3H,
wherein n is an integer from 0 to 10.

### Claim 2 (depends on 1)

The compound as in claim 1, wherein R1, R2, R3 and R4 are each independently H, OH, ═O or C1-5 alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound as in claim 1, wherein R1, R2, R3 and R4 are each independently H, or OH, and contains at least one or more OH; or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound as in claim 1, wherein R1, R2, R3 and R4 are each independently H, OH, ═O or C1-5 alkyl, and contains at least one or more ═O or C1-5 alkyl; or a pharmaceutically acceptable salt thereof.

### Claim at position 5

-10. (canceled)

### Claim 11 (depends on 1)

The compound as in claim 1, wherein X is substituted or unsubstituted C1-4 alkylene, and if substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-4 alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound as in claim 1, wherein A is —NR5R6C(O)—, —OR6, —SR6, —NR5R6, —C(O)R6, —C(O)OR6, —C(O)NR5R6, —CH(R5)(R6), —CH(R5)(OR6), —CH(OR5)(OR6), —CH(R5)(SR6), or —CH(SR5)(SR6), and wherein R5, R6 are characterized in that they are the same as the definition in claim 1; or a pharmaceutically acceptable salt thereof.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The compound as in claim 13, wherein R5 is H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C1-10 heteroalkyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted C3-20 heterocycloalkyl, substituted or unsubstituted C6-20 aryl, substituted or unsubstituted C1-10 alkyl-C6-20 aryl or substituted or unsubstituted C1-10 alkyl-C6-20 heteroaryl, and wherein if R5 is substituted, one or more hydrogen(s) is(are) substituted with linear or branched C1-5 alkyl, =O, ORa, SRa, N(Ra)2, or CON(Ra)2 and Ra is H or C1-5 alkyl; or a pharmaceutically acceptable salt thereof.

### Claim at position 11

-18. (canceled)

### Claim 19 (depends on 13)

The compound as in claim 13, wherein R6 is a bond, substituted or unsubstituted C1-10 alkylene, substituted or unsubstituted C1-10 heteroalkylene, substituted or unsubstituted C3-20 cycloalkylene, substituted or unsubstituted C3-20 heterocycloalkylene, or substituted or unsubstituted C6-20 arylene, and wherein if R6 is substituted, one or more hydrogen(s) is(are) substituted with =O, linear or branched C1-10 alkyl, C0-10 alkyl-C6-20 aryl or C0-10 alkyl-OH; or a pharmaceutically acceptable salt thereof.

### Claim at position 13

-22. (canceled)

### Claim 23 (depends on 1)

The compound as in claim 1, wherein R5 and R6 together form C3-10 cycloalkylene, C3-10 heterocycloalkylene, C6-10 arylene or C6-10 heteroarylene; or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 1)

The compound as in claim 1, wherein R5 and R6 together form
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

The compound as in claim 1, wherein Y is H, —(CH2)nCH3, —(CH2)n COOH, —(CH2)nOH, —(CH2)nSO3H or —(CH2)nOSO3H, and n is an integer from 0 to 10; or a pharmaceutically acceptable salt thereof.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The compound as in claim 1, wherein the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds:

### Claim 28 (depends on 1)

The compound as in claim 1, wherein the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is any one selected from the group consisting of the following compounds:
(wherein, Na+ can be replaced by other pharmaceutically acceptable salts).

### Claim 29 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 29)

A method for treating inflammatory diseases, which method comprises administering the pharmaceutical composition as in claim 29 to a subject in need thereof.
